We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current NP5 market cap is 176.85M. The company's latest EPS is EUR -0.9803 and P/E is -10.51.
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 4.03M | 7.04M | 5.26M | 5.76M | 6.09M |
| Operating Income | -14.66M | -20.9M | -18.07M | -12.36M | -13.3M |
| Net Income | -15.04M | -20.21M | -21M | -14.9M | -17.49M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 59.73M | 60.29M | 51.2M | 50.49M | 37.2M |
| Total Liabilities | 4.89M | 23.49M | 33.95M | 47.38M | 51.23M |
| Total Equity | 54.84M | 36.8M | 17.25M | 3.11M | -14.03M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -16.11M | -22.21M | -15.59M | -11.45M | -11.09M |
| Investing | 3.04M | -932k | -616k | 8.42M | -317k |
| Financing | 51k | 17.57M | 7.37M | 14.83M | -186k |
| Market Cap | 176.85M |
| Price to Earnings Ratio | -10.51 |
| Price to Sales Ratio | 30.16 |
| Price to Cash Ratio | 13.69 |
| Price to Book Ratio | -13.1 |
| Dividend Yield | - |
| Shares Outstanding | 17.85M |
| Average Volume (1 week) | 5.27k |
| Average Volume (1 Month) | 19.62k |
| 52 Week Change | 119.25% |
| 52 Week High | 13.30 |
| 52 Week Low | 3.82 |
| Spread (Intraday) | 0.09 (0.9%) |
| Company Name | Newron Pharmaceuticals Spa. |
| Address |
via antonio meucci 3, bresso milan, lombardy 20091 |
| Website | https://www.newron.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
